Enter your search terms:

A track record of success

In November 2018 we received FDA approval of Sympazan™ (clobazam) Oral Film. Sympazan is a film formulation of clobazam, a benzodiazepine used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).


For full Prescribing Information, including Boxed Warning on the risks of concomitant use with opioids, click here.


Please see full Prescribing Information, including Boxed Warning.

Partnering to make a difference

Aquestive has also demonstrated a strong track record of developing and manufacturing products for commercial partners. Aquestive works hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a development platform for new ones. Strategic partnerships are at the core of our business, whethercompanies want to leverage our PharmFilm technology for existing treatments that are in development or on the market. We are proud of our strong track record of more than 5 active partnerships and a product portfolio that has generated billions of dollars in revenue.



Partner Products Delivered on PharmFilm™ Technology Indication Approval Date Marketing Partner
Treatment of Opioid Dependence August 2010 INDIVIOR
Treatment of Nausea & Vomiting July 2010 Midatech

PharmFilm Marketed Products


Treatment of Opioid

Approval Date
August 10th

Marketing Partner


Treatment of Nausea
& Vomiting

Approval Date
July 2010

Marketing Partner

Sympazan™ Authorized Distributors of Record

See below for a listing of the Authorized Distributors of Record (ADRs) for Aquestive Therapeutics, Inc., in accordance with 21 C.F.R. § 203.50(d). If you have questions regarding this list, please contact Amy Santos at asantos@aquestive.com.


Authorized Distributors of Record

Latest comments

Sorry, the comment form is closed at this time.